This biotech manufacturer, a publicly listed joint venture of two companies affiliated with the Samsung conglomerate, brought in only $400 million in revenue in 2017. But through partnerships with Biogen and AstraZeneca, it holds a stake in the world’s largest pipeline for biosimilar generic drugs—a pipeline that analysts believe can generate annual revenue growth of 40% to 60% for years to come. In July, South Korean regulators ruled that the company violated accounting standards in structuring one of its partnerships and referred the case to prosecutors. In a statement, the company said its actions were legal.
Company Information
Overall Score | - |
Sector | Health Care |
Industry | Life Sciences Tools and Services |
CEO | Tae-Han Kim |
Website | http://www.samsungbiologics.com |
Employees | 1,767 |
HQ Location | Incheon, South Korea |
Revenues ($M) (Past 12 Months) | $501 |
Profits ($M) (Past 12 Months) | $-99 |
Market Value as of Oct. 10, 2018 ($M) | $28,326 |